Westbury, NY - BioIVT announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
The FNIH Biomarkers Consortium is a public-private biomedical research partnership. It brings together members of industry, academia, nonprofit and patient advocacy organizations, and government agencies and institutes to develop and support research to qualify promising biomarkers for diagnosing disease, predicting therapeutic response or improving clinical practice.
“We’re proud to contribute our research expertise to support the FNIH Biomarkers Consortium programs. Our research services groups will be able to assist in the development of new assays supporting diagnostic, efficacy and safety biomarker research for cancer, metabolic disorders, neuroscience, and inflammation and immunity applications,” said Amanda Woodrooffe, PhD, vice president and general manager, PHASEZERO® Research Services at BioIVT.
“We are excited to welcome BioIVT as the newest member of the FNIH Biomarkers Consortium. BioIVT’s expertise and commitment to scientific discovery will help us accelerate biomedical research to fight diseases across the world,” said Joseph P. Menetski, PhD, associate vice president for research partnerships, the FNIH.
For more information, please visitwww.bioivt.com or follow the company on Twitter @BioIVT.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.